Inhibition of FAM83D displays antitumor effects in glioblastoma via down-regulation of the AKT/Wnt/β-catenin pathway
- PMID: 35150198
- DOI: 10.1002/tox.23488
Inhibition of FAM83D displays antitumor effects in glioblastoma via down-regulation of the AKT/Wnt/β-catenin pathway
Abstract
Up-regulation of family with sequence similarity 83 member D (FAM83D) has been acknowledged as a vital contributor for the carcinogenesis of numerous cancers. The relevance of FAM83D in glioblastoma (GBM), however, is not well understood. This current work aimed to determine the possible roles and mechanisms of FAM83D in GBM. By analyzing The Cancer Genome Atlas (TCGA) data, we found dramatic increases in FAM83D expression in GBM tissue. We also observed elevated levels of FAM83D in the clinical specimens of GBM. In vitro data showed that silencing FAM83D resulted in remarkable antitumor effects via inhibiting the proliferation, invasion and epithelial-mesenchymal transition of GBM cells. Moreover, the knockdown of FAM83D improved sensitivity to the chemotherapy drug temozolomide. In-depth mechanism research revealed that the silencing of FAM83D strikingly decreased the phosphorylation levels of AKT and glycogen synthase kinase-3β, and prohibited activation of the Wnt/β-catenin pathway. The suppression of AKT abolished FAM83D-mediated activation of the Wnt/β-catenin pathway. The re-expression of β-catenin reversed FAM83D-silencing-induced antitumor effects in GBM cells. In addition, GBM cells with FAM83D silencing exhibited reduced tumorigenic potential in vivo. Overall, the data from this work show that the inhibition of FAM83D displays antitumor effects in GBM via down-regulation of the AKT/Wnt/β-catenin pathway and propose FAM83D as a new therapeutic target for GBM.
Keywords: AKT; FAM83D; Wnt; glioblastoma.
© 2022 Wiley Periodicals LLC.
Similar articles
-
SKA3 promotes glioblastoma proliferation and invasion by enhancing the activation of Wnt/β-catenin signaling via modulation of the Akt/GSK-3β axis.Brain Res. 2021 Aug 15;1765:147500. doi: 10.1016/j.brainres.2021.147500. Epub 2021 Apr 22. Brain Res. 2021. PMID: 33895155
-
LHPP exerts a tumor-inhibiting role in glioblastoma via the downregulation of Akt and Wnt/β-catenin signaling.J Bioenerg Biomembr. 2021 Feb;53(1):61-71. doi: 10.1007/s10863-020-09866-0. Epub 2021 Jan 4. J Bioenerg Biomembr. 2021. PMID: 33394310
-
miR-504 suppresses mesenchymal phenotype of glioblastoma by directly targeting the FZD7-mediated Wnt-β-catenin pathway.J Exp Clin Cancer Res. 2019 Aug 16;38(1):358. doi: 10.1186/s13046-019-1370-1. J Exp Clin Cancer Res. 2019. PMID: 31419987 Free PMC article.
-
Wnt and PI3K/Akt/mTOR Survival Pathways as Therapeutic Targets in Glioblastoma.Int J Mol Sci. 2022 Jan 25;23(3):1353. doi: 10.3390/ijms23031353. Int J Mol Sci. 2022. PMID: 35163279 Free PMC article. Review.
-
Regulatory role of miRNAs on Wnt/β-catenin signaling in tumorigenesis of glioblastoma.Indian J Cancer. 2023 Jul-Sep;60(3):295-302. doi: 10.4103/ijc.IJC_251_21. Indian J Cancer. 2023. PMID: 37787188 Review.
Cited by
-
The FBXW7-binding sites on FAM83D are potential targets for cancer therapy.Breast Cancer Res. 2024 Mar 7;26(1):37. doi: 10.1186/s13058-024-01795-9. Breast Cancer Res. 2024. PMID: 38454442 Free PMC article.
-
Pan-cancer analysis of the FAM83 family and its association with prognosis and tumor microenvironment.Front Genet. 2022 Jul 22;13:919559. doi: 10.3389/fgene.2022.919559. eCollection 2022. Front Genet. 2022. PMID: 35938024 Free PMC article.
References
REFERENCES
-
- Lim M, Xia Y, Bettegowda C, Weller M. Current state of immunotherapy for glioblastoma. Nat Rev Clin Oncol. 2018;15(7):422-442.
-
- Paolillo M, Boselli C, Schinelli S. Glioblastoma under siege: an overview of current therapeutic strategies. Brain Sci. 2018;8(1):15.
-
- Thomas AA, Brennan CW, DeAngelis LM, Omuro AM. Emerging therapies for glioblastoma. JAMA Neurol. 2014;71(11):1437-1444.
-
- Omuro A, De Angelis LM. Glioblastoma and other malignant gliomas: a clinical review. JAMA. 2013;310(17):1842-1850.
-
- Messaoudi K, Clavreul A, Lagarce F. Toward an effective strategy in glioblastoma treatment. Part I: resistance mechanisms and strategies to overcome resistance of glioblastoma to temozolomide. Drug Discov Today. 2015;20(7):899-905.
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
